Mar 31, 2018
Notes to the Standalone Financial Statements for the Year ended 31 st March, 2018.
1. Corporate information:
M/s.Transgene Biotek Limited is a Public Limited Company ("The Company").The Company is located in 68, 69 & 70, Anrich Industrial Area, Bollarum, Sangareddy District, India and was incorporated on 1 st March 1990 under the provisions of the Companies Act, 2013. The Company is in the business of Research & Development.
2. Significant accounting policies
2.1. Statement of Compliance
For all periods up to and including the year ended 31 March 2017, the Company prepared its financial statements in accordance accounting standards notified under the section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP). These financial statements for the year ended 31 March 2018 are the first the Company has prepared in accordance with Ind AS.
These financial statements are separate financial statements of the Company (also called standalone financial statements). The Company has prepared financial statements for the year ended March 31,2018 in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) together with the comparative period data as at and for the year ended March 31, 2017
2.2. Basis of preparation:
The financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time).
The financial statements have been prepared on a historical cost basis, except for the following assets and liabilities which have been measured at fair value:
i. Certain Non-Current& Current financial liabilities measured at amortized cost,
The Company''s Financial Statements are presented in Indian Rupees (Rs.), which is also its functional currency.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.
Fair value for measurement and/or disclosure purposes in these financial statements is determined on such a basis, except for measurements that have some similarities to fair value but are not fair value, such as net realizable value in Ind AS 2.
In addition, for financial reporting purposes, fair value measurements are categorized into Level 1,2, or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:
- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.
The Company has consistently applied the following accounting policies to all periods presented in these financial statements.
a. Current V/s. non-current classification
The Company presents assets and liabilities in the balance sheet based on current/ noncurrent classification.
An asset is treated as current when it is:
- Expected to be realized or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realized within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period
All other assets are classified as non-current.
A liability is current when:
- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period
The Company classifies all other liabilities as non-current.
The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle.
b. Foreign currencies
Transactions and balances
Transactions in foreign currencies are initially recorded by the Company''s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.
Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.
Exchange differences arising on settlement or translation of monetary items are recognized in profit or loss.
c. Segment Reporting
The Company is currently operating only in one segment of Bulk Drugs, Segment Wise Reporting is not applicable as per IND AS 108. However, a disclosure has been made showing Segment wise comparison with respect to previous years results. Refer
Note No. 32
d. Revenue recognition
Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made.
Sales tax/ value added tax (VAT) / Goods and Service Tax (GST) is not received by the Company on its own account. Rather, it is tax collected on value added to the commodity by the seller on behalf of the government. Accordingly, it is excluded from revenue.
The specific recognition criteria described below must also be met before revenue is recognized.
i) Rendering of services
Revenue for the company is in the form of Research and Development services to external agencies which is recognized on formal acceptance by the agency which is in consistent with the above mentioned principle of revenue recognition.
e. Government grants
When loans or similar assistance are provided by governments or related institutions, with an interest rate below the current applicable market rate, the effect of this favorable interest is regarded as a government grant. The loan or assistance is initially recognized and measured at fair value and the government grant is measured as the difference between the initial carrying value of the loan and the proceeds received. The loan is subsequently measured as per the accounting policy applicable to financial liabilities.
f. Property, plant and equipment
Under the previous GAAP (Indian GAAP), Freehold land and buildings (property), other than investment property, were carried in the balance sheet on the basis of carrying value as per previous GAAP as on date of balance sheet. The Company has elected to regard those values of property as deemed cost.
Capital work in progress is stated at cost, net of accumulated impairment loss, if any. Plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the plant and equipment. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives.
Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognized in profit or loss as incurred. The present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset if the recognition criteria for a provision are met.
Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows:
- Building 60 years
- Temporary Building 3 years
- Computers 3 years
- Plant and equipment 15 years
- Electrical Equipmentâs 0 years
- Furniture 8 years
- Office Equipmentâs years
- Vehicles 8 years
- Lab equipmentâs 10 years
An item of property, plant and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss when the asset is derecognized.
The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.
g. Intangible assets
Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. Internally generated intangibles, excluding capitalized development costs, are not capitalized and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred.
The useful lives of intangible assets are assessed as finite i.e. for a period of 10 years.
Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.
Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit or loss when the asset is derecognized.
h. Research and Development Expenditure
Research and Development Expenditure Revenue expenditure pertaining to research is charged to the Statement of Profit and Loss. Development costs of products are charged to the Statement of Profit and Loss unless a product''s technological and commercial feasibility has been established, in which case such expenditure is capitalized.
i. Finance costs
Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use.
Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.
Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.
All other borrowing costs are expensed in the period in which they occur.
j. Inventories
Inventories are valued at the lower of cost and net realizable value.
Costs incurred in bringing each product to its present location and condition are accounted for as follows:
- Raw materials: cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on first in, first out basis.
- Finished goods and work in progress: cost includes cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs. Cost is determined on first in, first out basis.
Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.
k. Cash and cash equivalents
For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes Cash on hand and other Balances with Banks in Current Accounts that are readily convertible into cash which are subject to insignificant risk of changes in value and are held for the purpose of meeting short-term cash commitments.
I. Cash flow statement
Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated. Bank overdrafts are classified as part of cash and cash equivalent, as they form an integral part of an entity''s cash management.
m. Tax Expenses
In view of the current year loss and the losses accumulated in the previous years no liability on income tax is expected. As there is no certainty in utilizing the deferred tax asset, hence, the deferred tax asset has not been recognized in the books of accounts.
n. Employee benefits
i) Short-term employee benefit obligations
Liabilities for wages and salaries including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees'' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.
ii) Post-employment benefits
Defined Contribution plan
Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than the contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as an expense, when an employee renders the related service. If the contribution payable to the scheme for service received before the balance sheet date exceeds the contribution already paid, the deficit payable to the scheme is recognized as a liability after deducting the contribution already paid. If the contribution already paid exceeds the contribution due for services received before the balance sheet date, then excess is recognized as an asset to the extent that the pre-payment will lead to, for example, a reduction in future payment or a cash refund.
Defined benefit plan
The Company operates a defined benefit gratuity plan and Leave Encashment in India for which provision has been for the year ended 31st March, 2018.
The Company is not in practice of providing any other Defined Benefit Plan to the employees for the year ended 31st March, 2018.
o. Contributed equity
Equity shares are classified as equity.
Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
p. Earnings per share
i) Basic earnings per share
Basic earnings per share is calculated by dividing:
- The profit attributable to owners of the company
- By the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares issued during the year and excluding treasury shares.
ii) Diluted earnings per share
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:
- the after income tax effect of interest and other financing costs associated with dilutive potential equity shares, and
- the weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares.
q. Provisions
General
Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.
The company has made 100% provision for the investment made in the Transgene Biotek HK Limited (Subsidiary) for Rs. 92,20,09,728/-. Further, 100% provision is made against payment made to M/s. Symetric Sciences Inc utilized out of GDR proceeds. This is without prejudice to the company''s claim in this regard.
r. Financial instruments
A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.
Financial assets
Initial recognition and measurement
All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the financial asset.
Derecognition
A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognized (i.e. removed from the Company''s balance sheet) when:
- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a ''pass-through'' arrangement? and either
(a) the Company has transferred substantially all the risks and rewards of the asset, or
(b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.
Financial liabilities
Initial recognition and measurement
Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives, as appropriate.
All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.
The Company''s financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts and derivative financial instruments.
Subsequent measurement
The measurement of financial liabilities depends on their classification, as described below: Financial liabilities at fair value through profit or loss
Financial liabilities at fair value through profit or loss include financial liabilities held for trading. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Gains or losses on liabilities held for trading are recognized in the profit or loss.
Loans and borrowings
After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the EIR method. Gains and losses are recognized in profit or loss when the liabilities are derecognized as well as through the EIR amortization process.
Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the statement of profit and loss.
Derecognition
A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit or loss.
Reclassification of financial assets and liabilities
The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets and financial liabilities. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognized gains, losses (including impairment gains or losses) or interest.
Reference is made about the long standing case at CESTAT, Chennai and the Honourable Member Ms. SulekhaBeevi C.S passed an order on 25th May 2017 stating that "the matter is stayed by the Hon''ble High Court of Madras. Both sides have not been able to submit when the matters are likely to be disposed by the Hon''ble High Court. Viewed in this light, we are of the considered opinion that it would be appropriate and prudent to close the file for the purpose of statistics. Both sides are at liberty to file application before the Tribunal to reopen the matter as and when the case is disposed by the Hon''ble High Court or in the case of change of circumstances." In view of the above order, no provision has been made in the current balance sheet but the management shall keep a cautious eye on the potential developments, if any and will act as per the requirements.
b. During the year 2014-15 one of the employees of the Company sustained severe burns in a fire incident in the Company. The Company helped him financially for hospitalization and treatment after which he was discharged from the hospital. However, after the discharge, for some unknown reasons he contracted infection and died while being treated for that. His family approached Labour Court claiming an unspecified amount for his death from the Company. The management has been defending the claim hence, no amount is provided for in books of account for the same as the Company is not sure of the liability
c. During the year 2016-17 the Company had received notice u/s 263 from the Principal Commissioner of the Income Tax for the Assessment year 2012-13 for which the company has filed its arguments. The case has been set aside by the Commissioner and a fresh notice has been served by the department on this regard for which the company is presenting its Arguments and the result is yet to be known
d. The Department of Biotechnology has sanctioned a loan amount of Rs.4.07 crores under Small Business Innovative Research Initiative (SBIRI) scheme for the novel technology up gradation for Orlistat production, for which a charge against movable and immovable assets acquired from utilization of the said loan amount has been created.
An amount of Rs.56,90,879 is demanded by SIBRI towards interest for which a provision has been made.
30. Related Party Disclosures Related Parties:
a) Key Managerial Personnel:
Dr. K. KoteswaraRao: Managing Director
b) Relatives to Key Managerial Personnel:
K. LaxmidharRao: Son of Managing director K.NirmalaRao: Wife of Managing director K. SrinivasaRao: Son of Managing Director
c) Subsidiaries
Transgene Biotek HK Limited : Wholly Owned Subsidiary
The following are the transactions made with Key Managerial personnel and related parties:
34. Standards issued but not effective
IND AS 115, Revenue from contracts with customers
In March 2018, the Ministry of Corporate Affairs has notified Ind AS 115, ''Revenue from Contracts with Customers'', which is effective for accounting periods beginning on or after 1 April 2018. This comprehensive new standard will supersede existing revenue recognition guidance, and requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and improve guidance for multiple-element arrangements Ind AS 115 is effective for annual reporting periods beginning on or after April 1,2018. The Company intends to adopt Ind AS 115 effective April 1, 2018, using the modified retrospective method. The adoption of Ind AS 115 is not expected to have a significant impact on the Company''s recognition of revenues
35. Other Amendments to Indian Accounting Standards:
The Ministry of Corporate Affairs (MCA), on 28 March 2018, issued certain amendments to Ind AS. The amendments relate to the following standards:
Ind AS 21, The Effects of Changes in Foreign Exchansge Rates - The amendment lays down the principle regarding advance payment or receipt of consideration denominated or priced in foreign currency and recognition of non-monetary prepayment asset or deferred income liability.
Ind AS 12, Income Taxes - The amendment explains that determining temporary differences and estimating probable future taxable profit against which deductible temporary differences are assessed for utilization are two separate steps and the carrying amount of an asset is relevant only to determining temporary differences.
Ind AS 28, Investments in Associates and Joint Ventures - The amendment clarifies when a venture capital, mutual fund, unit trust or similar entities elect to initially recognize the investments in associates and joint ventures.
Ind AS 112, Disclosure of Interests in Other Entities - The amendment clarifies that disclosure requirements for interests in other entities also apply to interests that are classified as Held for sale or discontinued operations in accordance with Ind AS 105.
Ind AS 40, Investment Property - The amendment clarifies when a property should be transferred to / from investment property.
The amendments are effective 1 April 2018. The Company believes that the aforementioned amendments will not materially impact the financial position, performance or the cash flows of the Company
Mar 31, 2015
A. Basis of preparation of financial statements :
The accompanying financial statements are prepared in accordance with
Indian Generally Accepted Accounting Principles (GAAP) under the
historical cost convention on the accruals basis. GAAP comprises
mandatory accounting standards issued by the Institute of Chartered
Accountants of India (ICAI), the provisions of the Companies Act, 2013
and guidelines issued by the Securities and Exchange Board of India.
Accounting policies have been consistently applied and management
evaluates all recently issued or revised accounting standards on an
ongoing basis.
1. Fixed Assets and Depreciation :
Fixed Assets are stated at cost less accumulated depreciation. Cost
includes all expenses related to acquisition and installation of the
concerned assets and, any attributable cost of bringing the asset to
the condition of its intended use.
Depreciation is provided under the straight-line method based on useful
life of assets as estimated by the Management. Depreciation is charged
on a monthly pro-rata basis for assets purchased / sold during the
year. Individual assets acquired for less than Rs. 5,000 are entirely
depreciated in the year of acquisition. The Management's estimate of
useful life for various fixed assets is as under :
Asset Useful life of Asset in years
Buildings 30
Lab Equipment 15
Mis.Fixed Assets 20
Air Conditioners 15
Office Equipment 15
Electrical Instillation 15
Generator 15
Furniture and Fixtures 15
Plant and Machinery 20
Vehicles 10
Technology 14
2. REVENUE RECOGNITION
Revenue for the company is from medical diagnostic services. Revenue
from sales and services are recognized on formal acceptance by the
customer/patient.
3. INVENTORIES
Raw Materials/Inventory - At Cost or the net realizable value whichever
is less. Cost is determined on a First in First out basis.
Finished Goods - At cost or net realizable value whichever is less.
4. Expenditure on the ongoing product development for "Meningitis
Vaccine, Erythropoietin, Tacrolimus, Statins ( Orlistat, Lovastatin
Pravastatin ), Cancer products and Oral Insulin will be capitalized and
written off over a period of the expected useful life of the respective
products after obtaining commercial license/commencement of commercial
production of the same.
(Amount in Rupees)
Opening Balance Additions * Closing Balance
31,98,85,402 Nil 31,98,85,402
* Total amount incurred on development of products during 2014-15
The management is of the opinion that the product development
expenditure incurred on the products is technically feasible to
generate future economic benefits and the company has sufficient
technical resources to complete it.
5. RETIREMENT BENEFITS
A) The Company is contributing to the Employees Provident fund
maintained under the Employees Provident Fund Scheme by the Central
Government.
B) Leave encashment is not provided during the year.
C) No provision is made towards the gratuity of employees.
6. INTERNALLY GENERATED INTANGIBLE ASSETS
Direct and indirect costs incurred during planning stage, and on
operational activities charged to revenue in the year in which it has
incurred.
Direct cost incurred on application & infrastructure development,
design and content development stages are capitalized if and only if
(i) it is probable that the future economic benefits that are
attributable to the asset will flow to the enterprise and (ii) the cost
of the asset can be measured reliably. Indirect cost incurred during
application, infrastructure, development stage are charged to revenue.
7. EARNINGS PER SHARE
In determining earnings per share, the company considers the net profit
after tax. The number of shares used in computing basic earnings per
share is the weighted average number of shares outstanding at the
during the year. The number of shares used in computing diluted
earnings per share comprises the weighted average shares outstanding
during the year.
8. CASH FLOW STATEMENT
Cash flows are reported using the indirect method, whereby net profit
before tax is adjusted for the effects of transactions of a non-cash
nature and any deferrals or accruals of past or future cash receipts or
payments. The cash flows from regular revenue generating, investing and
financing activities of the company are segregated. Cash flows in
foreign currencies are accounted at average monthly exchange rates that
approximate the actual rates exchange prevailing at the dates of the
transactions.
9. INCOME-TAX
Current tax is determined as the amount of tax payable in respect of
taxable income for the year.
As there is no virtual certainty in utilizing the deferred tax asset,
hence, the deferred tax asset has not been recognized in the books of
accounts.
Mar 31, 2014
A. Basis of preparation of financial statements:
The accompanying financial statements are prepared in accordance with
Indian Generally Accepted Accounting Principles (GAAP) under the
historical cost convention on the accruals basis. GAAP comprises
mandatory accounting standards issued by the Institute of Chartered
Accountants of India (ICAI), the provisions of the Companies Act, 1956
and guidelines issued by the Securities and Exchange Board of India.
Accounting policies have been consistently applied and management
evaluates all recently issued or revised accounting standards on an
ongoing basis.
1. Fixed Assets and Depreciation :
Fixed Assets are stated at cost less accumulated depreciation. Cost
includes all expenses related to acquisition and installation of the
concerned assets and, any attributable cost of bringing the asset to
the condition of its intended use.
Depreciation is provided under the straight-line method based on useful
life of assets as estimated by the Management. Depreciation is charged
on a monthly pro-rata basis for assets purchased / sold during the
year. Individual assets acquired for less than Rs. 5,000 are entirely
depreciated in the year of acquisition. The Management''s estimate of
useful life for various fixed assets is as under:
2. REVENUE RECOGNITION
Revenue for the company is from sales of products and medical
diagnostic services. Revenue from sales and services are recognized on
formal acceptance by the customer/patient.
3. INVENTORIES
Raw Materials/lnventory - At the cost or the net realizable value
whichever is less is considered. Cost is determined on a First in
First out basis.
Finished Goods - At the cost or the net realizable value whichever is
less is considered.
4. Expenditure on the ongoing product development for "Meningitis
Vaccine, Erythropoietin, Tacrolimus, Statins (Orlistat, Lovastatin
Pravastatin), Cancer products and Oral Insulin will be capitalized and
written off over a period of the expected useful life of the respective
products after obtaining commercial license/commencement of commercial
production of the same.
* Total amount incurred on development of products during 2013-14
The management is of the opinion that the product development
expenditure incurred on the products is technically feasible to
generate future economic benefits and the company has sufficient
technical resources to complete it.
5. RETIREMENT BENEFITS
A) The Company is contributing to the Employees Provident fund
maintained under the Employees Provident Fund Scheme by the Central
Government.
B) Leave encashment provided as per valuation certificate.
C) The Company is contributing to the Employees Gratuity fund
maintained under the GGCA Fund Scheme by the LIC of India.
6. INTERNALLY GENERATED INTANGIBLE ASSETS
Direct and indirect costs incurred during planning stage, and on
operational activities charged to revenue in the year in which it has
incurred.
Direct cost incurred on application & infrastructure development,
design and content development stages are capitalized if and only if
(i) it is probable that the future economic benefits that are
attributable to the asset will flow to the enterprise and (ii) the cost
of the asset can be measured reliably. Indirect cost incurred during
application, infrastructure, development stage are charged to revenue.
7. EARNINGS PER SHARE
In determining earnings per share, the company considers the net profit
after tax. The number of shares used in computing basic earnings per
share is the weighted average number of shares outstanding at the
during the year. The number of shares used in computing diluted
earnings per share comprises the weighted average shares outstanding
during the year.
8. CASH FLOW STATEMENT
Cash flows are reported using the indirect method, whereby net profit
before tax is adjusted for the effects of transactions of a non-cash
nature and any deferrals or accruals of past or future cash receipts or
payments. The cash flows from regular revenue generating, investing and
financing activities of the company are segregated. Cash flows in
foreign currencies are accounted at average monthly exchange rates that
approximate the actual rates exchange prevailing at the dates of the
transactions.
9. INCOME-TAX
Current tax is determined as the amount of tax payable in respect of
taxable income for the year.
As there is no virtual certainty in utilizing the deferred tax asset,
hence, the deferred tax asset has not been recognized in the books of
accounts.
Mar 31, 2011
A. Basis of preparation of financial statements:
The accompanying financial statements are prepared in accordance with
Indian Generally Accepted Accounting Principles (GAAP) under the
historical cost convention on the accruals basis. GAAP comprises
mandatory accounting standards issued by the Institute of Chartered
Accountants of India (ICAI), the provisions of the Companies Act, 1956
and guidelines issued by the Securities and Exchange Board of India.
Accounting policies have been consistently applied and management
evaluates all recently issued or revised accounting standards on an
ongoing basis.
1. Fixed Assets and Depreciation:
Fixed Assets are stated at cost less accumulated depreciation. Cost
includes all expenses related to acquisition and installation of the
concerned assets and, any attributable cost of bringing the asset to
the condition of its intended use.
Depreciation is provided under the straight-line method based on useful
life of assets as estimated by the Management. Depreciation is charged
on a monthly pro-rata basis for assets purchased / sold during the
year. Individual assets acquired for less than Rs. 5,000 are entirely
depreciated in the year of acquisition. Out of the total Depreciation
on Assets, 50% is transferred to Product development expenses account
as 50% of the assets is used for Product Development purpose. The
Management's estimate of useful life for various fixed assets is as
under:
Asset Useful life of Asset in years
Buildings 30 Lab Equipment 15 Mis.Fixed Assets 20 Air Conditioners 15
Office Equipment 15 Electrical Instillation 15 Generator 15 Furniture
and Fixtures 15 Plant and Machinery 20 Vehicles|;10
2. REVENUE RECOGNITION
Revenue for the company is from sales of products and medical
diagnostic services. Revenue from sales and services are recognized on
formal acceptance by the customer/patient.
3. INVENTORIES
Jlaw Materials - Aicosi or the net realizablevalue whichever is less is
considered. Cost is determined on a First in First out basis.
Finished Goods - There are no closing stocks of finished goods.
4. Expenditure on the ongoing product development for "Meningitis
Vaccine, Erythropoietin, Tacrolimus, Statins (Orlistat, Lovastatin,
Pravastatin), Cancer products and Oral Insulin will be capitalized and
written off over a period of the expected useful life of the respective
products after obtaining commercial license/commencement of commercial
production of the same.
The management is of the opinion that the product development
expenditure incurred on the products is technically feasible to
generate future economic benefits and the company has sufficient
technical and financial resources to complete it.
5. RETIREMENT BENEFITS
A) The Company is contributing to the Employees Provident fund
maintained under the Employees Provident Fund Scheme by the Central
Government.
B) Leave encashment will be debited to profit and loss account as and
when it has been paid.
C) The Company is contributing to the Employees Gratuity fund
maintained under the GGCA Fund Scheme by the LIC of India.
6. INTERNALLY GENERATED INTANGIBLE ASSETS
Direct and indirect costs incurred during planning stage, and on
operational activities charged to revenue in the year in which it has
incurred.
Direct cost incurred on application & infrastructure development,
design and content development stages are capitalized if and only if
(i) it is probable that the future economic benefits that are
attributable to the asset will flow to the enterprise and (ii) the cost
of the asset can be measured reliably. Indirect cost incurred during
application, infrastructure, development stage are charged to revenue.
7. EARNINGS PER SHARE
In determining earnings per share, the company considers the net profit
after tax. The number of shares used in computing basic earnings per
share is the weighted average number of shares outstanding at the
beginning of the year. The number of shares used in computing diluted
earnings per share comprises the weighted average shares outstanding
during the year.
8. CASH FLOW STATEMENT
Cash flows are reported using the indirect method, whereby net profit
before tax is adjusted for the effects of transactions of a non-cash
nature and any deferrals or accruals of past or future cash receipts or
payments. The cash flows from regular revenue generating, investing
and financing activities of the company are segregated. Cash flows in
foreign currencies are accounted at average monthly exchange rates that
approximate the actual rates exchange prevailing at the dates of the
transactions.
9. INCOME-TAX
Current tax is determined as the amount of tax payable in respect of
taxable income for the year. Deferred tax is not provided as per AS-22,
because of huge losses of the past year which have been carried forward
to this year.
Mar 31, 2010
1. BASIS OF PREPARATION OF FINANCIAL STATEMENTS:
The accompanying financial statements are prepared in accordance with
Indian Generally Accepted Accounting Principles (GAAP) under the
historical cost convention on the accrual basis. GAAP comprises
mandatory accounting standards issued by the Institute of Chartered
Accountants of India (ICAI), the provisions of the Companies Act, 1956
and guidelines issued by the Securities and Exchange Board of India.
Accounting policies have been consistently applied and management
evaluates all recently issued or revised accounting standards on an
ongoing basis.
2. FIXED ASSETS AND DEPRECIATION:
Fixed Assets are stated at cost less accumulated depreciation. Cost
includes all expenses related to acquisition and installation of the
concerned assets and, any attributable cost of bringing the asset to
the condition of its intended use.
Depreciation is provided under the straight-line method based on useful
life of assets as estimated by the Management. Depreciation is charged
on a monthly pro-rata basis for assets purchased / sold during the
year. Individual assets acquired for less than Rs. 5,000 are entirely
depreciated in the year of acquisition. Out of the total Depreciation
on Assets, 50% is transferred to Product development expenses account
as 50% of the assets is used for Product Development purpose. The
Managements estimate of useful life for various fixed assets is as
under:
3. REVENUE RECOGNITION
Revenue for the company is from sales of products and medical
diagnostic services. Revenue from sales and services are recognized on
formal acceptance by the customer/patient.
4. INVENTORIES
Raw Materials Valued at Cost
Finished Goods - There are no closing stocks of finished goods.
5. Expenditure on the ongoing product development for "Meningitis
Vaccine, Erythropoietin, Tacrolimus, Statins (Orlistat, Lovastatin
Pravastatin), Cancer products and Oral Insulin will be capitalized and
written off over a period of the expected useful life of the respective
products after obtaining commercial license/commencement of commercial
production of the same.
* Total amount incurred on development of products during 2009-10
The management is of the opinion that the product development
expenditure incurred on the products is technically feasible to
generate future economic benefits and the company has sufficient
technical and financial resources to complete it.
6. RETIREMENT BENEFITS
A) The Company is contributing to the Employees Provident fund
maintained under the Employees Provident Fund Scheme by the Central
Government.
B) Leave encashment will be debited to profit and loss account as and
when it has been paid.
7. INTERNALLY GENERATED INTANGIBLE ASSETS
Direct and indirect costs incurred during planning stage, and on
operational activities charged to revenue in the year in which it has
incurred.
Direct cost incurred on application & infrastructure development,
design and content development stages are capitalized if and only if
(i) it is probable that the future economic benefits that are
attributable to the asset will flow to the enterprise and (ii) the cost
of the asset can be measured reliably. Indirect cost incurred during
application, infrastructure, development stage are charged to revenue.
8. EARNINGS PER SHARE
In determining earnings per share, the company considers the net profit
after tax. The number of shares used in computing basic earnings per
share is the weighted average number of shares outstanding at the
beginning of the year. The number of shares used in computing diluted
earnings per share comprises the weighted average shares outstanding
during the year.
9. CASH FLOW STATEMENT
Cash flows are reported using the indirect method, whereby net profit
before tax is adjusted for the effects of transactions of a non-cash
nature and any deferrals or accruals of past or future cash receipts or
payments. The cash flows from regular revenue generating, investing and
financing activities of the company are segregated. Cash flows in
foreign currencies are accounted at average monthly exchange rates that
approximate the actual rates exchange prevailing at the dates of the
transactions.
10. INCOME-TAX
Current tax is determined as the amount of tax payable in respect of
taxable income for the year. Deferred tax is not provided as per AS-22,
because of huge losses of the past year which have been carried forward
to this year.
11. Previous year figures have been regrouped and reclassified
according to the groupings and classifications made for the current
financial year.